Navigation Links
Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
Date:12/16/2009

NEW YORK, Dec. 16 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today the initiation of a Phase 3 registration clinical trial for KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor, in relapsed / refractory multiple myeloma patients.

The trial, entitled, "A Phase 3 Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib (Velcade®) and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib" is a double-blind, placebo-controlled trial comparing the efficacy and safety of perifosine vs. placebo when combined with bortezomib (Velcade®) and dexamethasone. The trial will enroll approximately 400 patients with relapsed or relapsed / refractory multiple myeloma. The primary endpoint is progression-free survival and secondary endpoints include overall response rate, overall survival and safety. This trial is being conducted pursuant to a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA). Additionally, the FDA has granted perifosine Orphan Drug and Fast Track designations in this indication.

The Phase 3 trial is being led by the Principal Investigator, Dr. Paul Richardson, Clinical Director of the Jerome Lipper Multiple Myeloma Center, at Dana-Farber Cancer Institute (DFCI) in Boston, MA and Dr. Kenneth C, Anderson, Chief, Division of Hematologic Neoplasia at DFCI. An estimated 40 to 50 centers throughout the United States and select centers outside of the United States will be participating in this Phase 3 trial.

Dr. Richardson's clinical research focuses on studying novel therapies for multiple myeloma. He was the lead investigator of the

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... 2013 Although colonoscopy exams prevent many colon ... sensitive method for detecting colorectal cancers 2 , the ... 3 . EndoChoice ® Inc. today unveiled research ... the accuracy of this procedure and greatly reduces the ... discussing these clinical trial results and featuring the Fuse ...
(Date:5/18/2013)... 18, 2013 The Open Paradigm Project, ... Occupy Psychiatry , and leading organizations in ... a social media campaign showcasing video testimonials by ... which focuses on pathology and illness rather than ... American Psychiatric Association,s (APA) rollout of its latest ...
(Date:5/18/2013)... , May 18, 2013 Faruqi ... firm, is investigating potential securities fraud at AVEO ... (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... and its executives violated federal securities laws by ... Company,s Phase III drug trials for Tivopath (tivozanib) ...
Breaking Medicine Technology:New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2
... Ariz. , July 28 Matrixx Initiatives, Inc. (Nasdaq: MTXX ... 2011 first quarter ended June 30, 2010 , will be released after ... call will be held the following morning on Wednesday, August 4, 2010 ... , , ...
... Eli Lilly and Company (NYSE: LLY ) today announced that the ... by the U.S. District Court for the Eastern District of Michigan ... , , ... Gemzar,s method-of-use patent. We continue to believe that our Gemzar method-of-use patent should ...
Cached Medicine Technology:Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2011 First Quarter Financial Results 2U.S. Court of Appeals Rules on Validity of Lilly's Gemzar Method-of-Use Patent 2U.S. Court of Appeals Rules on Validity of Lilly's Gemzar Method-of-Use Patent 3
(Date:5/18/2013)... Cambridge House of Maryville , a ... East area, is hosting a Memorial Day Weekend Barbecue from ... The community, which is located at 6960 State Rte. 162 ... those on Medicaid, who need some help to maintain their ... off by homemade ice cream for dessert,” says Tracy Skaer-Henry, ...
(Date:5/18/2013)... Columbia (PRWEB) May 19, 2013 In “Cooking ... (published by iUniverse) , author Janet Hall Svisdahl’s new cookbook, ... recipes sure to make even the pickiest eater drool. ... pleasurably and prayerfully,” she explains. , Found within the ... a wide range of delicious recipes, from fast and simple ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Daily Gossip issued ... a new review on their page. John Colston, Daily Gossip’s ... to Shaun Hadsall’s revolutionizing 14-Day Rapid Fat Loss Plan ... sustain that carbs are healthy at a time when nutritionists ... from highly caloric products. , The diet is based ...
(Date:5/18/2013)... ORLANDO MAY 19, 2013 The American Society ... the field of endoscopy during the ninth annual ASGE ... ASGE and the ASGE Foundation, this year,s event will ... SeaWorld in Orlando, Fla. , Held in conjunction ... symbolize the finest in leadership, research and scientific pursuit. ...
(Date:5/18/2013)... Each year, the American Gastroenterological Association (AGA) recognizes ... in gastroenterology through its esteemed recognition awards. , ... individuals who work tirelessly to advance the science ... to announce the 2013 recognition award honorees who ... tremendous contributions to our field," said Loren Laine, ...
Breaking Medicine News(10 mins):Health News:Metro East Affordable Assisted Living Community to Host Memorial Day Weekend Barbecue 2Health News:Janet Hall Svisdahl Announces Release of ‘Cooking with Spirits for the Spirit’ 2Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 2Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 3Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 4Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 5Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 6Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 7Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 2Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 3Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 4Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 5
... project educates and empowers through personal stories across the South ... Washington D.C.,s AIDS rate is more than ten times ... Of people living with AIDS in Washington, D.C., 82 percent ... with World AIDS Day earlier in the week, the Southern ...
... Formed Platform To Be Developed In Partnership With Industry ... , SAN FRANCISCO, Dec. 1 Genstar ... focuses on investments in selected segments of the industrial ... services industries, today announced that it has signed a ...
... TorreyPines Therapeutics, Inc.,(Nasdaq: TPTX ) ... an,AMPA/kainate-type glutamate receptor antagonist, demonstrated a statistically,significant ... state) and allodynia (pain resulting from normally ... following intradermal injections of capsaicin in,a human ...
... Computer Services,Inc. (NYSE: ACS ) re-enters the ... government agencies lower costs and increase service.,With the expiration ... a few,agencies, ACS can now offer its proven business ... As the U.S. faces ...
... 2008 Dreams Come True event. , ... New York, NY (PRWEB) December ... a U.S. chapter of KCA College for Keep A Child Alive, a ... world. KCA College is an action-oriented network of college students who ...
... breast cancer who have undergone breast augmentation may ... called brachytherapy, according to a study presented today ... of North America (RSNA). Patients treated with brachytherapy ... of the implant hardening, compared to patients who ...
Cached Medicine News:Health News:Southern AIDS Living Quilt Coming to Washington, D.C. 2Health News:Genstar Capital Launches New Senior Care Services Platform UniVita Health and Agrees to Acquire Outsourced Insurance Services Provider, Long Term Care Group 2Health News:Genstar Capital Launches New Senior Care Services Platform UniVita Health and Agrees to Acquire Outsourced Insurance Services Provider, Long Term Care Group 3Health News:Genstar Capital Launches New Senior Care Services Platform UniVita Health and Agrees to Acquire Outsourced Insurance Services Provider, Long Term Care Group 4Health News:Genstar Capital Launches New Senior Care Services Platform UniVita Health and Agrees to Acquire Outsourced Insurance Services Provider, Long Term Care Group 5Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 2Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 3Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 4Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 5Health News:ACS Solutions for Federal Agencies: Meeting the Needs of a New Administration 2Health News:ACS Solutions for Federal Agencies: Meeting the Needs of a New Administration 3Health News:My Bank Tracker Sponsors "Keep A Child Alive" 2Health News:Breast cancer treatment offers better outcome to women with implants 2
Ophthalmic Nd Yag Laser with excellent quality optics for clear image and good laser delivery. Compact and light-weight for portability....
The compact size and portability of the Epic system makes it a cost-effective solution for single or multi-office use....
A conventional blue visibility-tinted daily-wear lens, custom made for astigmats with up to -3.00 D of cylinder requiring adds of up to +2.50 D....
A soft contact lens that lets presbyopes see clearly and comfortably at all distances , without the hassles of bifocals or reading glasses. Recommended for daily wear. Also approved for extended wear...
Medicine Products: